DSM Reports Steady Growth, Seeks Deal in Pharmaceuticals

08:49 AM | August 2, 2011 | Alex Scott

DSM has reported Ebitda for the second quarter of the year up 2% to €339 million ($482 million) on sales up 7% to €2.3 billion. Strong life sciences results were driven by robust growth in the group’s...